NCT00243568

Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285

Withdrawn Phase 3 Last updated 12 September 2019

What this trial tests

Phase 3 trial testing Vicriviroc in HIV Infections. Withdrawn.

Timeline

1 September 2005

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 September 2005

Drugs / interventions tested

• Vicriviroc — full drug profile →

Conditions studied

• HIV Infections — all drugs for HIV Infections →
• Acquired Immunodeficiency Syndrome — all drugs for Acquired Immunodeficiency Syndrome →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

18 and older, any sex, with HIV Infections or Acquired Immunodeficiency Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an international study of vicriviroc in 500 adult HIV-infected subjects who are failing standard antiretroviral therapy (ART). HIV must be of a certain type known as R5/X4-mixed tropic. Subjects allowed into the trial will be randomly assigned to treatment with vicriviroc 10 mg QD, vicriviroc 15 mg QD, or placebo in addition to other antiretrovirals (selected by the investigator to be optimal for the specific subject) containing at least 3 drugs, including a protease inhibitor (PI) boosted with at least 100 mg ritonavir QD. Subjects will be continued for up to 48 weeks of dosing.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Role of chemokine systems in cancer and inflammatory diseases.
   Li H, Wu M, Zhao X. · · 2022 · cited 85× · PMID 35702353 · DOI 10.1002/mco2.147